A Study in Adults With Desmoid Tumors

Recruiting now · Phase 2

Conditions studied: Desmoid Tumor

In brief

This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.

Key facts

Study ID

NCT07541430

Run by

Elpiscience (Suzhou) Biopharma, Ltd.

People needed

50

Starts

2026-04-30

Expected to finish

2028-10-01

Last updated by the study team

2026-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1) Histologically confirmed desmoid tumor.
• 2)Within 12 months prior to enrollment, meeting any of the following: Tumor target lesion growth ≥ 20% or appearance of new lesions;Desmoid tumor-related pain not adequately controlled by non-opioid medications.
• 3)Meeting any of the following conditions: Subjects with recurrence or disease progression after at least one line of treatment (including surgery, radiotherapy, or systemic therapy, etc.); Treatment-naive subjects who are deemed suitable for the study drug by the investigator.
• 4)Presence of at least one measurable lesion (according to RECIST v1.1).
• 5)Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.
• 6)Life expectancy of at least 12 weeks.
• 7)Adequate hematologic, hepatic, renal and coagulation functions per protocol.
• 8)Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception.

You may not qualify if…

• 1)Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β.
• 2)Receipt of any investigational agents or devices within 4 weeks prior to the first dose of study drug.
• 3)Prior treatment with any of the following:
• Anticancer therapy, including chemotherapy, tyrosine kinase inhibitors (TKIs), etc., within 28 days or 5 half-lives (whichever is shorter, but not less than 14 days) prior to the first dose of study drug.
• For subjects who have received radiotherapy, a washout period of at least 2 weeks (limb radiation) or 4 weeks (chest, brain, or visceral organ radiation) is required before the start of study drug administration.
• Traditional Chinese medicine (TCM) and proprietary Chinese medicines: if the package insert or investigator deems them to have clear anti-tumor effects, a 14-day washout is required. Other TCM and proprietary Chinese medicines do not require a washout.
• 4)Prior allogeneic or autologous bone marrow transplantation or solid organ transplantation.
• 5)Previous treatment-related toxicities unresolved to ≤ Grade 1, with the exception of alopecia (any grade), ≤ Grade 2 peripheral sensory neuropathy, and long-standing irreversible toxicities at the investigator's discretion.
• 6)Major surgery within 4 weeks prior to the first dose of study treatment.
• 7)Live vaccination therapies within 4 weeks prior to the first dose of study treatment.

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.